Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 04/17/2026 | CALL | $1,000.00 | 4,042 | +437 | +12.12% |
| 06/18/2026 | CALL | $1,050.00 | 947 | +294 | +45.02% |
| 04/10/2026 | CALL | $950.00 | 804 | +254 | +46.18% |
| 12/18/2026 | CALL | $1,200.00 | 878 | +248 | +39.37% |
| 04/10/2026 | PUT | $840.00 | 780 | +192 | +32.65% |
| 04/17/2026 | CALL | $1,100.00 | 3,365 | +178 | +5.59% |
| 04/17/2026 | CALL | $920.00 | 219 | -49 | -18.28% |
| 04/17/2026 | PUT | $1,060.00 | 83 | -84 | -50.30% |
| 04/17/2026 | CALL | $1,040.00 | 2,586 | -87 | -3.25% |
| 04/17/2026 | CALL | $955.00 | 399 | -100 | -20.04% |
| 04/10/2026 | CALL | $1,000.00 | 3,538 | -130 | -3.54% |
| 04/10/2026 | CALL | $980.00 | 769 | -721 | -48.39% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.74% | 26M | 11.45B |
| Vanguard 500 Index Fund | 1.92% | 18.23M | 8.03B |
| Vanguard/Primecap Fund | 1.56% | 14.85M | 6.54B |
| Fidelity 500 Index Fund | 0.91% | 8.65M | 3.81B |
| SPDR S&P 500 ETF Trust | 0.90% | 8.54M | 3.76B |
| Vanguard Specialized-Health Care Fund | 0.80% | 7.64M | 3.37B |
| iShares Core S&P 500 ETF | 0.74% | 7.04M | 3.1B |
| Washington Mutual Investors Fund | 0.73% | 6.95M | 3.06B |
| Growth Fund Of America Inc | 0.71% | 6.7M | 2.95B |
| Select Sector SPDR Fund-Health Care | 0.67% | 6.41M | 2.82B |
Here's Why Buying This Vanguard Index Fund Today Could Be the Best Financial Decision You Ever Make
04/10 03:15 pm
The Motley Fool
Read moreAtopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline
04/10 04:52 am
GlobeNewswire Inc.
Read moreAtopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033
04/10 04:46 am
GlobeNewswire Inc.
Read moreCrohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032
04/10 04:43 am
GlobeNewswire Inc.
Read moreFoghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
04/09 07:00 am
GlobeNewswire Inc.
Read moreEli Lilly Faces Pressure In India As Cheaper GLP-1 Rivals Dent Mounjaro Sales
04/09 06:44 am
Benzinga
Read moreTrogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model
04/09 02:00 am
GlobeNewswire Inc.
Read moreNxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
04/08 07:34 pm
GlobeNewswire Inc.
Read moreProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
04/08 04:00 pm
GlobeNewswire Inc.
Read moreLooks Like M&A Week in 3 Different Sectors
04/08 12:02 pm
The Motley Fool
Read moreIncyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
04/08 07:00 am
GlobeNewswire Inc.
Read moreAC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
04/07 07:00 am
GlobeNewswire Inc.
Read moreTrump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime
04/06 01:20 pm
Investing.com
Read moreEli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight
04/04 01:32 pm
The Motley Fool
Read moreWhy Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market
04/03 05:02 pm
The Motley Fool
Read moreWhere Will Viking Therapeutics Stock Be in 10 Years?
04/03 03:26 pm
The Motley Fool
Read moreDeal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy
04/03 10:35 am
Benzinga
Read moreDow, S&P 500, Nasdaq: From Morning Meltdown to Midday "Meh"
04/02 02:25 pm
The Motley Fool
Read moreLilly’s Next Empire: A $10 Billion Bet on AI and Neuroscience
04/02 01:51 pm
Investing.com
Read moreMerck Just Made a Big Bet on a New Cancer Growth Engine
04/02 11:32 am
Investing.com
Read moreTrump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: Report
04/02 04:44 am
Benzinga
Read morePrediction: This Will Be Eli Lilly's Next Billion-Dollar Growth Driver. (Hint: It's Not Weight Loss Drugs.)
04/02 04:15 am
The Motley Fool
Read moreWhy Eli Lilly Stock Trounced the Market Today
04/01 06:23 pm
The Motley Fool
Read moreStock Market Today, April 1: Markets Rally and Oil Prices Fall for Second Day Running
04/01 05:21 pm
The Motley Fool
Read moreAAVantgarde appoints Philip Lao as Senior Vice President of Business Development
04/01 07:00 am
GlobeNewswire Inc.
Read moreNxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly
03/31 07:43 pm
Benzinga
Read moreNxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
03/31 07:43 pm
GlobeNewswire Inc.
Read moreTrump Signals Iran Exit, S&P 500 Heads For Worst Month Since September 2022: What's Moving The Market On Tuesday?
03/31 01:27 pm
Benzinga
Read moreEli Lilly Expands Into Sleep Medicine With Centessa Buyout
03/31 10:48 am
Benzinga
Read moreStock Market Today, March 30: High Oil Prices Drive Risk-Off Sentiment, Nasdaq Falls 0.7%
03/30 05:26 pm
The Motley Fool
Read moreBile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030: Key Trends, Investment Opportunities and Competitive Strategies Analyzed
03/30 06:00 am
GlobeNewswire Inc.
Read morePrediction: Buying Pfizer Stock Today Could Set You Up for Life
03/29 08:15 pm
The Motley Fool
Read more1 Reason This Biotech Stock Could Triple Before Year-End
03/29 12:30 am
The Motley Fool
Read moreInstitutional Investors Are Selling One of Wall Street's Premier Trillion-Dollar Club Members (No, Not Nvidia!)
03/27 05:06 am
The Motley Fool
Read moreCould Buying Eli Lilly Today Set You Up for Life?
03/26 03:15 pm
The Motley Fool
Read moreSK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts
03/26 10:00 am
GlobeNewswire Inc.
Read moreSitryx to participate in upcoming April investor conferences
03/26 07:00 am
GlobeNewswire Inc.
Read moreIs Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?
03/25 09:36 am
Benzinga
Read moreThis Is the Most Important Thing Investors Can Do During a Volatile Market
03/24 02:10 pm
The Motley Fool
Read moreAbivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears
03/24 01:53 pm
Benzinga
Read moreEli Lilly To Phase Out Select Insulin Products Across Europe By 2027
03/24 09:20 am
Benzinga
Read moreWhat's Going On With Eli Lilly On Monday?
03/23 01:20 pm
Benzinga
Read moreAmphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs
03/23 08:00 am
GlobeNewswire Inc.
Read moreShould You Buy Eli Lilly Stock Before April 10?
03/22 05:10 am
The Motley Fool
Read moreMy Top 3 Drug Stocks for March 2026
03/20 06:30 am
The Motley Fool
Read more2 Healthcare Stocks to Buy Before They Get Bought Out
03/20 05:34 am
The Motley Fool
Read moreBest Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals
03/19 02:30 pm
The Motley Fool
Read moreEli Lilly Says Experimental Diabetes Drug Shows Weight Loss Of 17%
03/19 11:37 am
Benzinga
Read moreIs It Too Late to Buy Eli Lilly?
03/19 11:15 am
The Motley Fool
Read more